认知行为干预对晚期非小细胞肺癌靶向治疗患者自我感受负担的影响

Effect of cognitive behavior intervention on the self-perceived burden of patients with advanced non-small cell lung cancer accepting targeted therapy

目的探讨认知行为干预对晚期非小细胞肺癌靶向治疗患者自我感受负担(SPB)的影响。方法回顾性分析70例接受靶向治疗的晚期非小细胞肺癌患者的临床资料,将35例接受认知行为干预的患者作为观察组,将35例接受常规护理干预的患者作为对照组。对干预前后两组患者的SPB进行评估和比较。结果干预前,观察组与对照组患者的各量表得分比较,差异均无统计学意义(P﹥0.05)。干预后,观察组患者的一般自我效能感量表(GSES)、中国癌症患者化疗生活质量(QLQ-CCC)量表、面对量表得分均高于对照组患者,SPB量表、屈服量表得分均低于对照组患者(P﹤0.05);干预后,两组患者的回避量表得分比较,差异无统计学意义(P﹥0.05)。干预后,观察组患者的照护体力负担、经济负担、情感负担、社会负担、家庭负担及心理负担评分均明显低于对照组患者(P﹤0.01)。结论认知行为干预可有效缓解晚期非小细胞肺癌靶向治疗患者的SPB,值得临床推广应用。

Objective To study the effect of cognitive behavior intervention on the self-perceived burden(SPB)of patients with advanced non-small cell lung cancer accepting targeted therapy.Method The clinical data of70patients with advanced non-small cell lung cancer accepting targeted therapy were analyzed retrospectively,35cases accepted cognitive behavior intervention were divided into the observation group while35cases accepted regular nursing were divided into the control group.The SPB of patients before and after the intervention in the two groups was compared.Result Before the intervention,there was no significant difference in score of each scale between the two groups(P>0.05).After intervention,the general self-efficacy scale(GSES)score,the quality of life questionnaire for Chinese cancer patients with chemobiotherapy(QLQ-CCC)scale score,the face scale score of observation group were higher than those of the control group,the SPB score,the yield scale score of observation group was lower than those of the control group(P<0.05).After intervention,there was no significant differences in the score of avoid scale between the two groups(P>0.05).After intervention,the scores of physical care burden,economic burden,emotional burden,social burden,family burden and psychological burden of the observation group were significantly lower than those of the control group(P<0.01).Conclusion Cognitive behavior intervention could effectively relieve the SPB of patients with advanced non-small cell lung cancer accepting targeted therapy,which is worth promoting.